Equity
€332,427 from €713,934 in 2017
Equity fell by 53% in 8 years.
APOTHEEK LEENDERS
Lifetime
19 annual accounts with figures on one time axis, 37 filings since 1989peak €584,757 (2024)
€557,528▼ 4.7%
lowest -€9,460 (2008)
€105,225▲ 2.3%
peak €713,934 (2017)
€332,427▲ 0.1%
€1.0m▼ 7.0%
peak 5.7 FTE (2024)
5.5 FTE▼ 3.5%
Board4 names since 2020
1 directorDL PHARMACARE BV
Owners2 names in the annual accounts
100%DL PHARMACARE
Documentsfilings and deeds
14-08-202614 days late
2025abbreviated format
Company renamed from APOTHEEK FOULON to APOTHEEK LEENDERS 01-121 director appointed, 1 resignation 16-10Dividend €105,000Cash from €326,205 to €440,598
Key points
from the 2025 annual accountsDebts
€1.0m 75% of the balance sheet
Financial debts 58%Suppliers 22%Taxes and wages 4%Other 17%
Of this, €437,263 falls due within a year.
Staff
7 employees on 31-12-2025
In 2025, 1 person joined and 1 left.
Liquidity
2.21 was 1.29 in 2024
Short-term debts fell from €752,065 to €437,263.
Filings
37 annual accounts since 1989
Five of the last ten came late. The 2019 accounts came latest: 60 days after the end of the period.
Board
1 left
A director left. Latest change 01-12-2025 · 1 in office.
Checked score
93
Excellent
Financially stronger than 57% of micro companies in retail trade (NACE 47)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.6% across 40,276 companies (NACE 47, micro).
About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.3%
01-2025: 0.3%● unchanged vs 12-2024
02-2025: 0.3%● unchanged vs 01-2025
03-2025: 0.3%● unchanged vs 02-2025
04-2025: 0.3%● unchanged vs 03-2025
05-2025: 0.3%● unchanged vs 04-2025
06-2025: 0.3%● unchanged vs 05-2025
07-2025: 0.2%▼ -0.1 percentage points vs 06-2025
08-2025: 0.2%● unchanged vs 07-2025
09-2025: 0.2%● unchanged vs 08-2025
10-2025: 0.2%● unchanged vs 09-2025
11-2025: 0.2%● unchanged vs 10-2025
12-2025: 0.2%● unchanged vs 11-2025
01-2026: 0.2%● unchanged vs 12-2025
02-2026: 0.2%● unchanged vs 01-2026
03-2026: 0.2%● unchanged vs 02-2026
04-2026: 0.2%● unchanged vs 03-2026
05-2026: 0.2%● unchanged vs 04-2026
06-2026: 0.2%● unchanged vs 05-2026
07-2026: 0.3%▲ +0.1 percentage points vs 06-2026
08-2026: 0.6%▲ +0.3 percentage points vs 07-2026highest value
09-2026: 0.1%▼ -0.5 percentage points vs 08-2026lowest value
10-2026: 0.1%● unchanged vs 09-2026lowest value
11-2026: 0.1%● unchanged vs 10-2026lowest value
Financial strengthStrong
Score breakdown
raises risk
Sector: Retail trade (NACE 47)
Equity €332,427 (24.6% of total assets)
lowers risk
Liquidity: current ratio 2.21, cash €440,598
Founded in 1988
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 40% of them on solvency, 82% on liquidity, 68% on profitability and 39% on growth.
The bankruptcy probability was computed on 07-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 3,818 companies had the same profile as APOTHEEK LEENDERS has now. Each dot stands for 10 companies, two years later.
95.1%
were still trading
3.7%
stopped another way
1.0%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of APOTHEEK LEENDERS itself: 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 3,818 companies, not a prediction for APOTHEEK LEENDERS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €30,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 2.21 (1.29 in 2024), above the usual 1.5. Short-term debt is 32.3% and cash 32.5% of total assets. However, 75.4% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises risk
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025Equity per financial year
1819202122232425
2018 to 2025 · latest year €332,427
raises risk · 2025 accounts filed 14 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 14-08-2026, 14 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
14 days late
2024
42 days early
2023
23 days late
2022
25 days late
2021
3 days early
2020
12 days late
2019
60 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 13 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 14 August (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
07-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
- DL PHARMACARE 100%score 91equity €56,107 (2025) · 2025 annual accounts of DL PHARMACARE
Recent changes
Company renamed from APOTHEEK FOULON to APOTHEEK LEENDERS
Resignation: FOULON Petra (director) · Director discharge: FOULON Petra · General meeting of 24-11-2025 · Gazette deed
1 director appointed, 1 resignation
Resignation: DF PHARMA SERVICES BV · Permanent representatives: FOULON Petra and LEENDERS Nikki · Appointment: DL PHARMACARE BV · General meeting of 12-09-2025 · Gazette deed
Environmental permit granted
Verbouwen en/of uitbreiden van bijgebouwen en niet overdekte lage constructies · Oudsbergen
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0434764094
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| APOTHEEK LEENDERS Oudsbergen | €1.4m | €557,528 | 24.6% | 5.5 |
| PHARMACIE DU BALLON Charleroi | €1.4m | €493,174 | 31.5% | 5.7 |
| APOTHEEK DE NEVE Heusden-Zolder | €1.2m | €588,858 | 7.7% | 4.4 |
| APOTHEEK DU FAUX Destelbergen | €1.3m | €510,646 | 40.7% | 5.8 |
| PHARMACIE DE LA CHAPELLE Perwez | €1.3m | €534,442 | 23.3% | 5.6 |
| Apotheek Leenesonne Damme | €1.3m | €595,872 | 64.1% | 6.2 |
| ENBA Bonheiden | €1.5m | €528,409 | 55.7% | 4.8 |
These companies have the same main activity as APOTHEEK LEENDERS: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1.2m and €1.5m, founded between 1984 and 1994.
Official details
Source: KBO- Status
- Active since 30-06-1988Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2025
- Establishment unit
- 2.039.298.4053670 Oudsbergen, since 25-07-1988
- Financial year end
- 31 December
- Peppol
- Reachable since 12-09-2025
Annual accounts 2025
- ≈ €2.0mestimated
- €1.4m▼ 5.3%
- Employeeson 31-12-2025
- 7=
- Filing
- Filed on 14-08-2026
Insights on APOTHEEK LEENDERS
APOTHEEK LEENDERS files the abbreviated format. That format states no turnover. The gross margin rose from €161,206 in 2007 to €557,528 in 2025.
The balance sheet grew most from 2014 to 2016 through fixed assets.
DL PHARMACARE holds all the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about APOTHEEK LEENDERS
- What is the company number of APOTHEEK LEENDERS?
- The company number of APOTHEEK LEENDERS is 0434.764.094. The VAT number is the same number with BE in front: BE 0434.764.094.
- Where is APOTHEEK LEENDERS based?
- The registered office is at Hoogstraat 68, 3670 Oudsbergen.Company details
- What does APOTHEEK LEENDERS do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of APOTHEEK LEENDERS?
- APOTHEEK LEENDERS is a private limited company (BV).
- When was APOTHEEK LEENDERS founded?
- APOTHEEK LEENDERS was founded on 30-06-1988.
- Is APOTHEEK LEENDERS still active?
- Yes, APOTHEEK LEENDERS is an active enterprise in the KBO register.
- How many employees does APOTHEEK LEENDERS have?
- APOTHEEK LEENDERS had an average of 5.5 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does APOTHEEK LEENDERS fall under?
- In its 2025 annual accounts, APOTHEEK LEENDERS states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of APOTHEEK LEENDERS?
- The turnover in financial year 2025 is ≈ €2.0m. This figure is estimated from the gross margin of €557,528 and 47 comparable companies (NACE 477). It probably lies between €1.5m and €3.1m.
- Is APOTHEEK LEENDERS profitable?
- In financial year 2025, APOTHEEK LEENDERS made a profit of €105,225.
- Where can I find the annual accounts of APOTHEEK LEENDERS?
- APOTHEEK LEENDERS filed 37 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of APOTHEEK LEENDERS due?
- APOTHEEK LEENDERS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.